capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
pharma · Duchenne Muscular Dystrophy · Gastroparesis · PCSA
Processa Pharmaceuticals
Processa Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hanover, USA HQ
16 Employees
Public company Type
PCSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Hanover, USA
- Employees
- 16
- Programs
- 8
- Drugs
- 2
- Patents
- 0
Processa Pharmaceuticals pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Processa Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Processa Pharmaceuticals in public FDA and regional records.